Herpes Simplex Virus (HSV-1/2)
Prophylactic Vaccines Forecast
An estimated 520 million people aged 15-49 live with HSV-2 worldwide, and around 3.8 billion people under 50 carry HSV-1, yet no prophylactic vaccine exists for either. The mRNA era briefly drew Moderna and BioNTech into the field alongside GSK; both GSK and Moderna have since discontinued their (largely therapeutic-focused) candidates, leaving BioNTech's BNT163 as the field's leading active prophylactic contender. This is the independent, wide-geography commercial assessment of what a genuinely preventive HSV vaccine could still be worth, drawing on VacZine Analytics' long standing, independent authority in STD and adolescent vaccine markets. A companion analysis of therapeutic HSV vaccines is covered separately in VacZine Analytics' MarketVIEW VAMV038.
- Format
- Executive presentation (~175 slides) + Excel model
- Coverage
- 60 nations, public & private
- Indications
- Genital & neonatal HSV prevention
- Forecast horizon
- To 2040
- Approach
- Scenario-based demand model
- Base edition
- June 2022 edition
- Availability
- Syndicated / bespoke
with HSV-1 worldwide (WHO, 2025)
with HSV-2 worldwide (WHO, 2025)
disseminated neonatal herpes
in clinic: BioNTech's BNT163
A vast, mostly silent burden, and still no vaccine to prevent it
Herpes simplex virus is one of the most widespread infections in humanity, and while antiviral therapy can manage symptomatic disease once acquired, nothing today can stop a person acquiring HSV-1 or HSV-2 in the first place. That gap, and why it still matters commercially, is the starting point for this analysis.
Pathogen overview - Herpes simplex virus (HSV-1/HSV-2)
Herpes simplex virus types 1 and 2 are ubiquitous members of the human herpesvirus family, transmitted by oral or genital contact and establishing lifelong latent infection in sensory ganglia following primary exposure. Both types cause oral, ocular and/or genital infection, with genital ulcer disease (GUD) among the most consequential clinical manifestations. Most individuals infected with HSV-1/2 have minimal or no recognised signs of infection, but persons with GUD can experience frequent disease reactivation with a considerable impact on sexual and reproductive health and psychological wellbeing.
WHO's most recent global modelling (updated May 2025, based on 2020 data) estimates that 3.8 billion people under age 50 (64%) globally have HSV-1 infection, and a further 520 million people aged 15-49 (13%) have HSV-2 infection, the main cause of genital herpes. An estimated 205 million people aged 15-49 (5.3%) experienced at least one symptomatic episode of genital herpes in 2020, 92% of them related to HSV-2. These are modest upward revisions on the figures used in this report's original June 2022 edition, which cited 2016-based WHO estimates of 491 million HSV-2 infections (13.2% prevalence) and 3.7 billion HSV-1 infections worldwide. HSV-2 infects women almost twice as often as men, because sexual transmission is more efficient from men to women, and prevalence is markedly higher in lower-income regions.
Neonatal herpes remains rare, occurring in an estimated 10 per 100,000 births globally, but it is among the most severe outcomes in all of neonatal infectious disease: for infants with disseminated or CNS-involving disease left untreated, mortality has historically been estimated at 60 to 85%, with survivors frequently left with lasting neurologic disability. The risk is greatest when a mother acquires HSV for the first time in late pregnancy, which is precisely the scenario a prophylactic vaccine, deployed before or during the reproductive years, is best placed to prevent.
HSV-2 is also a significant, and historically under-appreciated, contributor to global HIV incidence: WHO's 2025 update puts the increased risk of HIV acquisition associated with HSV-2 infection at approximately three-fold, a relationship of particular importance in low-income, high-HIV-burden settings. Antiviral treatments such as aciclovir, famciclovir and valaciclovir can suppress viral replication, reduce symptomatic recurrence and lower (though not eliminate) the risk of onward transmission, but none is curative and none prevents acquisition in the first place. Given the sheer scale of global HSV prevalence and its contribution to the HIV epidemic, a genuinely effective prophylactic vaccine, ideally deployed in adolescence before sexual debut in a manner analogous to HPV immunisation, remains an outstanding unmet need. New mRNA-focused entrants briefly renewed interest in exactly this problem, though the field has narrowed considerably since this report's original 2022 edition, as set out below.
A narrowing field, and mRNA's one remaining prophylactic contender
Prophylactic HSV vaccine development has a long, largely disappointing history. GSK and Moderna both discontinued their leading HSV candidates in 2025, following decades of earlier setbacks including Genocea's GEN-003. That leaves BioNTech's BNT163, developed with the University of Pennsylvania, as the field's most advanced active prophylactic programme.
-
BioNTech & Univ. of PennsylvaniaPhase 1, ongoingBNT163 Trivalent mRNA, prophylactic
A trivalent mRNA vaccine encoding three HSV-2 glycoproteins, designed to prevent viral cellular entry and spread and to counteract the immunosuppressive properties of HSV, developed with Professor Drew Weissman's laboratory at the University of Pennsylvania. The first-in-human, dose-escalation Phase 1 trial (NCT05432583) is assessing safety and immunogenicity in adults aged 18-55 without prior symptomatic genital herpes; the most recent immunogenicity data were published in January 2026 in Open Forum Infectious Diseases. BNT163 is now the only prophylactic HSV vaccine from a major biopharma still in active clinical development. -
ModernaDiscontinued, November 2025mRNA-1608
A primarily therapeutic HSV-2 candidate; its Phase 1/2 trial (NCT06033261), begun in 2023, wrapped in spring 2025. Moderna announced on 20 November 2025 that it would not advance the programme to Phase 3, part of a wider pipeline-prioritisation exercise that also discontinued its shingles (mRNA-1468) and congenital CMV programmes. Included here for completeness, since its exit narrows the mRNA HSV field materially even though mRNA-1608 was not itself a prophylactic candidate. -
GSKDiscontinued, September 2025GSK3943104A
A recombinant protein, therapeutic candidate aimed at reducing recurrent genital herpes episodes; GSK announced in September 2025 that the programme had failed its Phase 2 primary efficacy endpoint. This was GSK's second failed HSV attempt, following an earlier terminated self-amplifying mRNA candidate, GSK4108771A. GSK's exit left Moderna and BioNTech as the field's remaining well-resourced developers, before Moderna's own withdrawal two months later. -
Sanofi PasteurDormant since Phase 1HSV529 Replication-defective, prophylactic
An earlier replication-defective prophylactic candidate that completed Phase 1 testing; no evidence of active follow-on clinical development has emerged since. Retained in this review as part of the field's longer prophylactic research history and as a reminder of how many earlier attempts have stalled after early-phase testing. -
Rational VaccinesPreclinical / early-stageRVx-2001 (HSV-2) & RVx-1001 (HSV-1)
Preventive candidates from a live-attenuated lineage originating in the late William Halford's academic research, alongside the company's more advanced therapeutic candidate, RVx201. Development is supported in part by NIH funding; as of this edition, the preventive candidates remain preclinical/early-stage and are not yet in registered human prophylactic trials.
No prophylactic or therapeutic HSV vaccine has ever been licensed, and the list of discontinued programmes is long: Genocea halted its T-cell candidate GEN-003 in 2017 to refocus on oncology, and 2025 alone saw both GSK and Moderna exit the field. Against that backdrop, BNT163's continued progression through Phase 1, on the same mRNA platform that underpinned the COVID-19 vaccines, is a genuine, if still early, signal rather than a validated result. A vaccine that could demonstrably prevent HSV-2 acquisition, particularly if deployable in adolescence ahead of sexual debut, would represent a real commercial and public health first after decades of failed attempts. The VacZine Analytics model quantifies the value of that opportunity across multiple pipeline-progression scenarios and 60 nations.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, target product profile design, the R&D competitive landscape and scenario-based demand forecasting across 60 nations, public and private, to 2040.
Scenario-based demand modelling to 2040 across 60 nations, spanning North America, Europe, ROW and GAVI-eligible markets, public and private.
Full review of BioNTech's BNT163 and the discontinued Moderna, GSK, Sanofi and Rational Vaccines programmes that preceded it.
Ideal target product profile assessment and clinical development pathway issues relevant to prophylactic HSV vaccine commercialisation.
Volume and value forecasts to 2040 across primary and secondary target cohorts, reflecting BNT163's pipeline progression and alternative scenarios.
Full global burden review across genital HSV, GUD and neonatal herpes, updated with WHO's May 2025 global estimates.
Designed as an ideal tool to aid early-stage decision making in prophylactic HSV vaccine development, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Indication | Geography | Target group | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Genital HSV prevention | North America | Adolescent (pre-sexual debut) | Phase 1 | Modelled |
| Neonatal herpes prevention | Europe | Women of reproductive age | Phase 1 | Modelled |
| Genital HSV prevention | ROW / GAVI-eligible | Adolescent | Preclinical / early-stage | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All groups | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the prophylactic HSV vaccine opportunity across public and private markets worldwide.
- Executive presentation (~175 slides) - disease background, global burden, target product profile, clinical development issues and full competitive environment review
- MS-Excel scenario-based forecast model - demand outputs to 2040 across primary and secondary target cohorts in 60 nations
- Wide geography coverage - North America, Europe, ROW and GAVI-eligible markets modelled separately and together, public and private
- Competitor intelligence - BioNTech's BNT163 and the discontinued Moderna, GSK, Sanofi and Rational Vaccines programmes
- Updated epidemiology module - WHO's May 2025 global burden update alongside the HIV-incidence link and neonatal herpes outcomes
- Early decision-making support - ideal target product profile and market entrance strategy guidance for early-stage prophylactic HSV vaccine planning
Built for organisations evaluating the prophylactic HSV opportunity
Most valuable to teams assessing the prophylactic HSV vaccine market against their own pipeline, BD ambitions or investment thesis, at a moment when the field has narrowed to a single active clinical-stage candidate.
Vaccine developers
Positioning, target product profile and commercial feasibility assessment for prophylactic HSV candidates at any stage.
Corporate strategy & BD
Validate the size and structure of a market with no incumbent prophylactic vaccine, now that BNT163 is the field's clear clinical-stage leader.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on BioNTech and future prophylactic HSV entrants.
Public health & immunisation programmes
Demand modelling to support future adolescent immunisation and neonatal herpes prevention programme planning in high-burden regions.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant, translational and HIV-prevention co-benefit planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public and private channels in both developed and GAVI-eligible markets.
VacZine Analytics has long standing expertise in STDs, having tracked adolescent and sexual health vaccine markets since our earliest editions, positioning us to reassess the prophylactic HSV opportunity through the mRNA era's rise and, for most of the field's candidates, its subsequent retreat. This is a genuinely comprehensive analysis with a wide geographic focus spanning 60 nations, public and private, and it has been well received by clients in the field for the depth of its target product profile and disease burden review. Few groups have followed this historically difficult market as closely, and that recognised, independent expertise underpins everything in the analysis.
This report was last published in June 2022. A refresh would incorporate WHO's May 2025 global burden update, GSK's and Moderna's 2025 discontinuations, and BioNTech's BNT163, now the field's only active clinical-stage prophylactic candidate. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc prophylactic HSV vaccine analysis, a briefing call is included on request.